In this rebroadcast AMA, Peter Attia and co-host Nick Stenner focus on blood pressure as a major, often under-addressed driver of cardiovascular and overall risk. Attia explains what systolic and diastolic readings represent and summarises current diagnostic thresholds (normal <120/<80; “elevated” 120–129/<80; stage 1 hypertension 130–139 or 80–89; stage 2 ≥140 or ≥90). He describes evidence from SPRINT and STEP, arguing that more intensive systolic targets (around 120) reduced major cardiovascular events, and he cites SPRINT MIND as suggesting a reduction in dementia risk with intensive treatment.
A substantial segment is devoted to measurement technique and why office readings can be misleading. Attia lists common sources of error—cuff size, arm position, recent activity, talking, pain, and a full bladder—and advises repeated home readings under standardised conditions. He notes blood pressure should typically “dip” overnight by 10–20%.
On management, Attia emphasises weight loss and aerobic exercise as high-impact interventions, with additional discussion of sodium sensitivity, potassium-rich foods, and sleep quality. He also outlines first-line drug classes (thiazide diuretics, calcium channel blockers, ACE inhibitors, ARBs), discusses circumstances that might influence choice, and argues ARBs are generally preferable to ACE inhibitors based on his team’s review. He closes with a warning against “biohacking” while neglecting basic risk factors such as hypertension.
Peter Attia says his team’s internal “white paper” concluded ARBs are at least as effective as ACE inhibitors and may be slightly better on side effects overall. He adds ACE inhibitors are often cheaper or more widely covered, and says cough is a common ACE-inhibitor side effect.
Read this moment →